Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Xiwang Sugar Industry is a Chinese corn deep-processing and starch-sugar manufacturer that operates as a subsidiary of Xiwang Group. The company produces crystalline fructose, dextrose monohydrate, dextrose anhydrous, maltodextrin, sodium gluconate, starch and related corn-derived ingredients for food, industrial and pharmaceutical uses. Available public sources indicate it is a large-scale manufacturing business rather than a drug-development biotech company, although it supplies pharma-grade glucose and related materials and reportedly holds multiple drug approval numbers in China. Its operations appear centered on high-volume corn processing and commercial supply rather than therapeutic R&D.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Xiwang Sugar Industry.